The Relationship between Anti-Mullerian Hormone Level and the Severity of Systemic Lupus Erythematosus in Women at Reproductive Age

Document Type : Original Article (s)

Authors

1 Assistant Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Resident, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Systemic lupus erythematosus (SLE) is a common autoimmune disease, and if not diagnosed and treated in a timely manner, can lead to irreversible complications such as lupus nephritis. Thus, the early detection of the disease is very important. On the other hand, some studies have shown that there is a relationship between the serum levels of anti-Mullerian hormone (AMH) and the activity of lupus disease. The aim of this study was to determine the relationship between antibody titer with severity and activity level of SLE.Methods: In a cross-sectional study, 70 women in age range of 18-35 years old with SLE who referred to rheumatology clinic of Alzahra hospital, Isfahan, Iran, were selected. Lupus activity was determined using SLE Disease Activity Index-2000 (SLEDAI-2k) score, and serum level of AMH was measured; and the relationship between SLE activity and serum level of AMH was evaluated.Findings: Mean serum level of AMH was 1.49 ± 1.58 ng/ml, ranging from 0.20 to 7.36; and thus, 11 patients (15.7%) had low levels of the hormone. Moreover, there was a statistically significant inverse correlation between disease activity scores and serum levels of AMH, as much as 0.46 (P < 0.001).Conclusion: The results of our study showed a relation between lupus activity and serum AMH. Especially, among the patients under treatment with corticosteroids and cyclophosphamide pulse therapy, there were lower levels of AMH; and this might lead to ovarian reserve loss and fertility problems in women of childbearing age.

Keywords

References

  1. Isenberg DA. Systemic lupus erythematosus - management. In: Watts RA, Conaghan PG, Denton C, Foster H, Isaacs J, Muller-Ladner U, editors. Oxford textbook of rheumatology. 4th ed. New York, NY: Oxford University Press; 2013. p. 734-43.
  2. Wallace DJ, Dubois EL. Definition, classification and epidemiology of systemic lupus erythematosus. In: Wallace DJ, Dubois EL, editors. Dubois lupus erythematosus. Philadelphia. PA: Lea and Febiger; 2005. p. 20-32.
  3. Cotran RS, Kumar V, Rubbins SL. Disease of immunity. In: Cotran RS, Kumar V, Rubbins SL, editors. Robbins pathologic basis of disease. Philadelphia, PA: W.B. Saunders; 2009. p. 185-259.
  4. Kim WU, Min JK, Lee SH, Park SH, Cho CS, Kim HY. Causes of death in Korean patients with systemic lupus erythematosus: A single center retrospective study. Clin Exp Rheumatol 1999; 17(5): 539-45.
  5. Gauzere L, Gerber A, Renou F, Ferrandiz D, Bagny K, Osdoit S, et al. Epidemiology of systemic lupus erythematosus in Reunion Island, Indian Ocean: A case-series in adult patients from a University Hospital. Rev Med Interne 2019; 40(4): 214-9. [In French].
  6. Chakravarty EF, Sammaritano LR. pregnancy and autoimmune disease, reproductive and hormonal issue. In: Wallace D, Hahn B, editors. Dubois' lupus erythematosus and related syndromes. 9th ed. Philadelphia, PA: Elsevier; 2018. p. 499-519.
  7. Tal R, Seifer DB. The role of antimullerian hormone in assisted reproduction. In: Leung PCK, Adashi EY, editors. The Ovary. 3rd ed. Cambridge, MA: Academic Press; 2019. p. 403-14.
  8. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr Rev 2009; 30(5): 465-93.
  9. Altutunji AZ, Liu L, Cai J, Wang Z, Gao Y. The effect of acupuncture on anti-mullerian hormone and assisted reproduction outcome in Polycystic Ovary Syndrome patients undergoing in vitro fertilization. J Pak Med Assoc 2019; 69(Suppl 3)(8): S4-S8.
  10. Mok CC, Chan PT, To CH. Anti-mullerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum 2013; 65(1): 206-10.
  11. Gasparin AA, Souza L, Siebert M, Xavier RM, Chakr RM, Palominos PE, et al. Assessment of anti-Mullerian hormone levels in premenopausal patients with systemic lupus erythematosus. Lupus 2016; 25(3): 227-32.
  12. Wei W, Lin Q, Huang Q, Tang H, Wang L, Wang G, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women before receiving cyclophosphamide therapy: Evaluation using anti-mullerian hormone. Advances in Reproductive Sciences 2016; 4(1): 17-22.
  13. Skomsvoll JF, Ostensen M, Baste V, Irgens LM. Number of births, interpregnancy interval, and subsequent pregnancy rate after a diagnosis of inflammatory rheumatic disease in Norwegian women. J Rheumatol 2001; 28(10): 2310-4.
  14. Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous cyclophosphamide. Lupus 2004; 13(9): 673-8.
  15. Lawrenz B, Henes J, Henes M, Neunhoeffer E, Schmalzing M, Fehm T, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: Evaluation by using anti-Muellerian hormone. Lupus 2011; 20(11): 1193-7.
  16. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF 3rd. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril 2007; 87(1): 101-6.
  17. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimullerian hormone and obesity: insights in oral contraceptive users. Contraception 2010; 81(3): 245-8.
Journal of Isfahan Medical School
Volume 37, Issue 541 - Serial Number 541
July and August 2019
Pages 1054-1060

Files

History

  • Receive Date: 10 August 2019
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics